Onconic Therapeutics Inc.

This study tests a new drug called JPI-547 combined with bevacizumab in people whose ovarian cancer has returned after prior treatment with platinum chemotherapy and PARP inhibitors. About 81 participants will receive either the new drug combination or standard care to see if it …

This study tests a new drug, JPI-547, combined with the chemotherapy irinotecan for people with advanced stomach cancer that has come back or spread. It is for patients who have already tried at least two other treatments. The goal is to see if the combination is safe and can shr…

This study tests a new medicine called JP-1366 for people with non-erosive GERD (NERD), a condition causing heartburn without visible damage to the esophagus. About 321 adults who have heartburn and acid regurgitation but no ulcers will take the drug or a placebo. The goal is to …

This study tests how a single dose of JPI-547 moves through the body in healthy men of Korean, Caucasian, and Chinese backgrounds, and whether taking it with food changes those levels. 36 participants will each receive the drug under different conditions to measure safety and dru…